WHO approves China’s Sinopharm vaccine

Published May 8, 2021
A box for a Covid-19 vaccine is displayed at an exhibit by Chinese pharmaceutical firm Sinopharm at the China International Fair for Trade in Services in Beijing on September 5, 2020. — AP/File
A box for a Covid-19 vaccine is displayed at an exhibit by Chinese pharmaceutical firm Sinopharm at the China International Fair for Trade in Services in Beijing on September 5, 2020. — AP/File

GENEVA: The World Health Organisation approved a Covid-19 vaccine from China’s state-owned drugmaker Sinopharm for emergency use on Friday, a boost to Beijing’s push for a big role in inoculating the world.

The vaccine, one of two main Chinese coronavirus vaccines that collectively have already been given to hundreds of millions of people in China and elsewhere, is the first developed by a non-Western country to win WHO backing. It is also the first time the WHO has given emergency use approval to a Chinese vaccine for any infectious disease.

A WHO emergency listing is a signal to national regulators that a product is safe and effective. It also allows it to be included in COVAX, a global programme to provide vaccines mainly for poor countries, which has hit supply problems.

“This expands the list of Covid -19 vaccines that COVAX can buy, and gives countries confidence to expedite their own regulatory approval, and to import and administer a vaccine,” WHO Director-General Tedros Adhanom Ghebreyesus told a briefing.

The WHO had already given emergency approval to Covid -19 vaccines developed by Pfizer-BioNTech, AstraZeneca, Johnson & Johnson and, last week, Moderna.

The decision to approve Sinopharm’s vaccine was taken by WHO’s technical advisory group, which began meeting on April 26 to review the latest clinical data as well as Sinopharm’s manufacturing practices.

A separate group of WHO experts, the Strategic Advisory Group of Experts (SAGE), voiced concern this week over data provided by Sinopharm on the risk of serious side-effects in some patients, but was confident in the vaccine’s ability to prevent disease, according to a document reviewed by Reuters.

Tedros said that, following the approval, SAGE had recommended that adults over 18 receive two doses of the Sinopharm vaccine.

SAGE found an efficacy of 78.1 per cent after two doses in multi-country Phase III clinical trials, according to the document. The vaccine’s developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group, had announced an efficacy of 79.34pc.

The WHO has said it could reach a decision on China’s other main Covid-19 vaccine, made by Sinovac Biotech, as soon as next week. The technical experts reviewed it on Wednesday.

China has deployed around 65 million doses of the Sinopharm vaccine and more than 200 million doses of the Sinovac shot. Both have been exported to many countries, particularly in Latin America, Asia and Africa, many of which have had difficulty securing supplies of vaccines developed in the West.

Published in Dawn, May 8th, 2021

Opinion

A dangerous bargain
Updated 17 Jun 2021

A dangerous bargain

Budget for FY22 faces massive risks such as inflation and a resurgence of the trade deficit.
The Falmouth diet
17 Jun 2021

The Falmouth diet

The Charter is an obsequious affirmation of US’s papacy.

Editorial

Shameful behaviour
17 Jun 2021

Shameful behaviour

Both opposition and treasury members should create space for opinions to be heard and aired.
17 Jun 2021

Sindh budget

A CURSORY reading of the Sindh budget 2021-22 reinforces the impression that Chief Minister Murad Ali Shah’s...
17 Jun 2021

West on China

IN what seems like a distinct return to Cold War rhetoric, the Western bloc has issued back-to-back statements...
Centre-Sindh tension
Updated 16 Jun 2021

Centre-Sindh tension

Such an adversarial state of affairs is not sustainable without damaging the working of the federation.
16 Jun 2021

Punjab budget

PUNJAB is where the battle for power will be fought in 2023. Punjab is also where PTI parliamentarians are perhaps...
16 Jun 2021

Haj decision for women

WHILE this year’s Haj will again be marked by a limited number of pilgrims, the Saudi government’s decision to...